佳學(xué)基因遺傳病基因檢測(cè)機(jī)構(gòu)排名,三甲醫(yī)院的選擇

基因檢測(cè)就找佳學(xué)基因!

熱門(mén)搜索
  • 癲癇
  • 精神分裂癥
  • 魚(yú)鱗病
  • 白癜風(fēng)
  • 唇腭裂
  • 多指并指
  • 特發(fā)性震顫
  • 白化病
  • 色素失禁癥
  • 狐臭
  • 斜視
  • 視網(wǎng)膜色素變性
  • 脊髓小腦萎縮
  • 軟骨發(fā)育不全
  • 血友病

客服電話

4001601189

在線咨詢

CONSULTATION

一鍵分享

CLICK SHARING

返回頂部

BACK TO TOP

分享基因科技,實(shí)現(xiàn)人人健康!
×
查病因,阻遺傳,哪里干?佳學(xué)基因準(zhǔn)確有效服務(wù)好! 靶向用藥怎么搞,佳學(xué)基因測(cè)基因,優(yōu)化療效 風(fēng)險(xiǎn)基因哪里測(cè),佳學(xué)基因
當(dāng)前位置:????致電4001601189! > 基因課堂 > 精準(zhǔn)治療 > 婦科腫瘤 >

【佳學(xué)基因檢測(cè)】卵巢癌精準(zhǔn)治療:馮煒煒教授

【佳學(xué)基因】卵巢癌精準(zhǔn)治療:馮煒煒教授,佳學(xué)基因?qū)ёx: 上海交通大學(xué)附屬瑞金醫(yī)院馮煒煒教授因致力于研究子宮體腫瘤的精準(zhǔn)診療,卵巢癌復(fù)發(fā)、轉(zhuǎn)移的表觀遺傳調(diào)節(jié)機(jī)制,而成為國(guó)際知

佳學(xué)基因檢測(cè)】卵巢癌精準(zhǔn)治療:馮煒煒教授

遺傳病、罕見(jiàn)病基因檢測(cè)導(dǎo)讀:

上海交通大學(xué)附屬瑞金醫(yī)院馮煒煒教授因致力于研究子宮體腫瘤的精準(zhǔn)診療,卵巢癌復(fù)發(fā)、轉(zhuǎn)移的表觀遺傳調(diào)節(jié)機(jī)制,而成為國(guó)際知名的卵巢癌、子宮體腫瘤精準(zhǔn)治療專家。

馮煒煒教授簡(jiǎn)介:

馮煒煒教授馮煒煒,上海醫(yī)科大學(xué)醫(yī)學(xué)博士和挪威Bergen大學(xué)博士,美國(guó)M.D. Anderson 癌癥中心博士后,教授,博士生導(dǎo)師,現(xiàn)任上海交通大學(xué)醫(yī)學(xué)院附屬瑞金醫(yī)院婦產(chǎn)科主任,住院醫(yī)師規(guī)范化培訓(xùn)瑞金醫(yī)院婦產(chǎn)科專業(yè)基地主任,兼任中國(guó)醫(yī)師協(xié)會(huì)婦產(chǎn)科醫(yī)師分會(huì)婦科腫瘤專業(yè)委員會(huì)委員,上海市醫(yī)師協(xié)會(huì)婦科腫瘤學(xué)醫(yī)師分會(huì)委員會(huì)委員,世界華人婦產(chǎn)科醫(yī)師協(xié)會(huì)NOTES微創(chuàng)醫(yī)學(xué)專業(yè)委員會(huì),中國(guó)醫(yī)師協(xié)會(huì)整合醫(yī)學(xué)分會(huì)上海盆底專業(yè)委員會(huì)副主任委員,中國(guó)婦幼保健協(xié)會(huì)婦科智能(AI)醫(yī)學(xué)專業(yè)委員會(huì)委員,上海市婦科質(zhì)控專家委員會(huì)委員,第五屆上海市醫(yī)學(xué)會(huì)醫(yī)療事故技術(shù)鑒定專家,上海市藥學(xué)會(huì)第十一屆藥物治療專業(yè)委員會(huì)委員,《現(xiàn)代婦產(chǎn)科進(jìn)展》第五屆編委會(huì)編委等。從事臨床工作25年,對(duì)婦科常見(jiàn)和疑難病有豐富診療經(jīng)驗(yàn),主攻方向?yàn)閶D科腫瘤的綜合診治。擅長(zhǎng)腹腔鏡手術(shù)和機(jī)器人手術(shù),熟練掌握廣泛子宮切除、腹主動(dòng)脈旁淋巴清掃等婦科高難度手術(shù),四級(jí)手術(shù)量200例/年以上??蒲蟹矫?,擅于從臨床治療實(shí)踐中凝練科學(xué)問(wèn)題,目前主要研究方向是子宮體腫瘤的精準(zhǔn)診療,卵巢癌復(fù)發(fā)、轉(zhuǎn)移的表觀遺傳調(diào)節(jié)機(jī)制。目前共獲得國(guó)家自然科學(xué)基金委和上海市科委等項(xiàng)目資助10項(xiàng),發(fā)表論文70余篇,第一作者或通訊作者發(fā)表SCI 收錄論著35篇,論文被選中國(guó)際會(huì)議(2010年IGCS)口頭發(fā)言1次。 

瑞金醫(yī)院馮煒煒教授

馮煒煒教授致力于腫瘤精準(zhǔn)醫(yī)學(xué)人才的培養(yǎng)與先進(jìn)治療技術(shù)的推廣

2018年4月起 中國(guó)醫(yī)師協(xié)會(huì)整合醫(yī)學(xué)分會(huì) 上海盆底專業(yè)委員會(huì)副主任委員
2015.12-2019.12 上海市藥學(xué)會(huì)第十一屆藥物治療專業(yè)委員會(huì)委員
2016.4- 上海市醫(yī)學(xué)會(huì)婦科腫瘤??品謺?huì)第二屆委員會(huì)子宮內(nèi)膜癌學(xué)組副組長(zhǎng)
2012-2016: 上海市醫(yī)學(xué)會(huì)婦科腫瘤??品謺?huì)第一屆委員會(huì)青年委員
2018.6 上海醫(yī)師協(xié)會(huì)婦科腫瘤分會(huì)第一屆委員會(huì)委員
2010- 國(guó)際婦科腫瘤協(xié)會(huì)(IGCS)會(huì)員
 

馮煒煒教授所承擔(dān)的國(guó)家及各級(jí)研究課題

17411950504 高齡產(chǎn)婦瘢痕子宮及相關(guān)胎盤(pán)疾病的早期預(yù)測(cè)及標(biāo)準(zhǔn)化干預(yù)模式研究 上海市科委 2017-10~2020-09 45萬(wàn)元 子課題負(fù)責(zé)人
20172003 利用循環(huán)腫瘤DNA監(jiān)測(cè)高危子宮內(nèi)膜癌和卵巢癌復(fù)發(fā)轉(zhuǎn)移的探索性研究 交大醫(yī)學(xué)院高原高峰人才計(jì)劃 2017-07~2020-06 100萬(wàn)元 課題負(fù)責(zé)人
16411953500 子宮內(nèi)膜癌臨床數(shù)據(jù)倉(cāng)庫(kù)建設(shè)和精準(zhǔn)診療模型研究 上海市科學(xué)技術(shù)委員會(huì)生藥處重點(diǎn)項(xiàng)目 2016-07~2019-09 50萬(wàn)元 課題負(fù)責(zé)人
81572836 組蛋白甲基化酶SMYD3在調(diào)節(jié)卵巢癌種植轉(zhuǎn)移中的作用 國(guó)家自然科學(xué)基金面上項(xiàng)目 2016-01~2019-12 68.4萬(wàn)元 課題負(fù)責(zé)人
 

馮煒煒教授在國(guó)際婦科腫瘤精準(zhǔn)治療領(lǐng)域的突出成就


Zhu Menhan, Jia Nan, Huang Feifei, Liu Xiaoxia, Zhao Yuqing, Tao Xiang, Jiang Wei, Li Qin, Feng Weiwei. (通訊作者) Whether intermediate-risk stage 1A, grade 1/2, endometrioid endometrial cancer patients with lesions larger than 2?cm warrant lymph node dissection? BMC Cancer. 2017 17(1):696 
Jia Nan, Chen Y, Tao Xiang, Ou E, Lu Xin, Feng Weiwei. (通訊作者) A gestational choriocarcinoma of the ovary diagnosed by DNA polymorphic analysis: a case report and systematic review of the literature.  J Ovarian Res.  2017 10(1):46. 
Jiang Wei, Chen Jun, Tao Xiang, Huang Feifei, Zhu Menghan, Wang Chao, Feng Weiwei (通訊作者) Possible Risk Factors of Pulmonary Metastases in Patients With International Federation of Gynecology and Obstetrics Stage I Endometrioid-Type Endometrial Cancer. Int J Gynecol Cancer 2017 27(6):1206-1215 
Jia Nan, Wang Jieyu, Li Qing, Tao Xiang, Chang Kaikai, Hua Keqin, Yu Yinhua, Wong Kwong-Kwok, Feng Weiwei (通訊作者) DNA methylation promotes paired box 2 expression via myeloid zinc finger 1 in endometrial cancer Oncotarget 2016 7(51):84785-84797 
Wang Jieyu, Jia Nan, Li Qing, Wang Chao, Tao Xiang, Hua Keqin, Feng Weiwei (通訊作者) Analysis of recurrence and survival rates in grade 3 endometrioid endometrial carcinoma. Oncology Letters  2016 12(4):2860-2867 
Chao Wang, Weiwei Feng (共同第一作者), Chuyao Zhang. The Expression and Function of NUMB in Endometrial Cancer and the Interaction with HDM2 and P53 Journal of Cancer. 2015 6(10): 1030-1040 
Menghan Zhu, Yuan He, Jan PA Baak, Xianrong Zhou, Yuqing Qu, Long Sui, Weiwei Feng and Qing Wang Factors that influence persistence or recurrence of high-grade squamous intraepithelial lesion with positive margins after the loop electrosurgical excision procedure: a retrospective study BMC Cancer 2015 20;15:744-751 
Zhang Chuyao, Hu Weiguo, Jia Nan, Li Qing, Hua Keqin, Tao Xiang, Wang Li, Feng Weiwei (通訊作者) Uterine Carcinosarcoma and High-Risk Endometrial Carcinomas: A Clinicopathological Comparison. Int J Gynecol Cancer. 2015 25(4):629-636. 
Jia Nan, Li Qing, Tao Xiang, Wang Jieyu, Hua Keqin, Feng Weiwei (通訊作者) Enhancer of zeste homolog 2 is involved in the proliferation of endometrial carcinoma.  Oncology Letters 2014 8(5):2049-2054. 
Qing Li, Xiang Tao, Guofu Zhang, Weiwei Feng (通訊作者) Leukemoid reaction in cervical cancer: a case report and review of the literature BMC Cancer.  2014 14:670 -677 
Lu Zhiying, Zhang Ying, Yan Xaohui, Chen Yisong, Tao Xiang, Wang Jiajia, Jia Nan, Lyu Tianjiao, Wang Junyan, Ding Jingxin, Feng Weiwei (通訊作者), Hua Keqin Estrogen stimulates the invasion of ovarian cancer cells via activation of the PI3K/AKT pathway and regulation of its downstream targets E cadherin and α actinin 4. Mol Med Rep.  2014 10(5):2433-40 
Xiaohui Yan, Tianjiao Lyu., Nan Jia, Yinhua Yu, Keqin Hua, Weiwei Feng (通訊作者) Huaier Aqueous Extract Inhibits Ovarian Cancer Cell Motility via the AKT/GSK3b/b-Catenin Pathway.  Plos One.  2013 8(5): e63731 
Lyu Tianjiao, Jia Nan, Wang Jieyu, Yan Xiaohui, Yu Yinhua, Lu Zhen, Bast RC Jr, Hua Keqin, Feng Weiwei (通訊作者) Expression and epigenetic regulation of angiogenesis-related factors during dormancy and recurrent growth of ovarian carcinoma. Epigenetics.  2013 17;8(12): 
Feng Weiwei*, Malpica Anais, Skaland I, Gudlaugsson E, Robboy SJ, Dalen I, Hua K, Zhou Xianrong, Baak JP Can proliferation biomarkers reliably predict recurrence in world health organization 2003 defined endometrial stromal sarcoma, low grade?  PLoS One.  2013 8(10):e75899 
Feng Weiwei, Hua Keqin, Anais Malpica, Zhou Xianrong, Baak Jan.P.  Stages I-II WHO2003 Defined Endometrial Stromal Sarcoma, Low Grade: How Much Primary Therapy Is Needed and How Little Is Enough? International Journal of Gynecological Cancer 2013 23(3):488-93 
Feng Weiwei (通訊作者), Hua Keqin, Gudlaugsson Einar, Yu Yinhua, Zhou Xianrong, Baak P.Jan.  Prognostic indicators in WHO 2003 low-grade endometrial stromal sarcoma.  Histopathology.  2013 62(5):675-87 
Feng Weiwei (通訊作者), Malpica Anais, Yinhua Yu, Janssen Emiel, Gudlaugsson Einar, Zhou Xianrong, Baak Jan P Diagnostic and prognostic morphometric features in WHO2003 invasive endometrial stromal tumours. . Histopathology.  2013 62(5):688-694 
Feng Weiwei* (通訊作者), Malpica Anias, Robboy Stanley J, Gudlaugsson Einar, Hua Keqin, Zhou Xianrong, Baak Jan P Prognostic Value of the Diagnostic Criteria Distinguishing Endometrial Stromal Sarcoma, Low Grade From Undifferentiated Endometrial Sarcoma, 2 Entities Within the Invasive Endometrial Stromal Neoplasia Family Int J Gynecol Pathol.  2013 32(3):299-306 
Chuyao Zhang, Chao Wang, and Weiwei Feng*. (通訊作者) Clinicopathological Risk Factors for Pelvic Lymph Node Metastasis in Clinical Early-Stage Endometrioid Endometrial Adenocarcinoma. International Journal of Gynecological Cancer.  2012 22, 1373-1377.


 

(責(zé)任編輯:佳學(xué)基因)
頂一下
(1)
100%
踩一下
(0)
0%
來(lái)了,就說(shuō)兩句!
請(qǐng)自覺(jué)遵守互聯(lián)網(wǎng)相關(guān)的政策法規(guī),嚴(yán)禁發(fā)布色情、暴力、反動(dòng)的言論。
評(píng)價(jià):
表情:
用戶名: 驗(yàn)證碼: 點(diǎn)擊我更換圖片

Copyright © 2013-2033 網(wǎng)站由佳學(xué)基因醫(yī)學(xué)技術(shù)(北京)有限公司,湖北佳學(xué)基因醫(yī)學(xué)檢驗(yàn)實(shí)驗(yàn)室有限公司所有 京ICP備16057506號(hào)-1;鄂ICP備2021017120號(hào)-1

設(shè)計(jì)制作 基因解碼基因檢測(cè)信息技術(shù)部